Indaptus Therapeutics, Inc.
INDP
$6.52
-$0.55-7.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.29M | 1.76M | 1.69M | 1.68M | 2.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.46M | 4.57M | 4.17M | 3.14M | 4.11M |
| Operating Income | -4.46M | -4.57M | -4.17M | -3.14M | -4.11M |
| Income Before Tax | -5.23M | -4.53M | -4.13M | -3.07M | -4.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.23M | -4.53M | -4.13M | -3.07M | -4.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.23M | -4.53M | -4.13M | -3.07M | -4.02M |
| EBIT | -4.46M | -4.57M | -4.17M | -3.14M | -4.11M |
| EBITDA | -4.46M | -4.57M | -4.17M | -3.14M | -4.11M |
| EPS Basic | -9.10 | -9.00 | -10.59 | -9.04 | -13.16 |
| Normalized Basic EPS | -5.68 | -5.62 | -6.62 | -5.65 | -8.22 |
| EPS Diluted | -9.10 | -9.00 | -10.59 | -9.04 | -13.16 |
| Normalized Diluted EPS | -5.68 | -5.62 | -6.62 | -5.65 | -8.22 |
| Average Basic Shares Outstanding | 574.90K | 503.70K | 390.20K | 339.70K | 305.10K |
| Average Diluted Shares Outstanding | 574.90K | 503.70K | 390.20K | 339.70K | 305.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |